Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Debt to Equity: 2023-2025

Historic Debt to Equity for Xeris Biopharma Holdings (XERS) over the last 3 years, with Sep 2025 value amounting to -$254.90.

  • Xeris Biopharma Holdings' Debt to Equity fell 47848.04% to -$254.90 in Q3 2025 from the same period last year, while for Sep 2025 it was -$254.90, marking a year-over-year decrease of 47848.04%. This contributed to the annual value of -$7.84 for FY2024, which is 74.69% up from last year.
  • Xeris Biopharma Holdings' Debt to Equity amounted to -$254.90 in Q3 2025, which was down 2,150.69% from -$11.33 recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Debt to Equity peaked at $4.53 during Q3 2023, and registered a low of -$254.90 during Q3 2025.
  • Its 3-year average for Debt to Equity is -$27.82, with a median of -$0.53 in 2024.
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 74.69% in 2024, then tumbled by 51,905.27% in 2025.
  • Xeris Biopharma Holdings' Debt to Equity (Quarterly) stood at -$30.97 in 2023, then skyrocketed by 74.69% to -$7.84 in 2024, then plummeted by 47,848.04% to -$254.90 in 2025.
  • Its last three reported values are -$254.90 in Q3 2025, -$11.33 for Q2 2025, and -$6.54 during Q1 2025.